Tuesday, June 13, 2023

Program subject to change.

07:15 - 08:15 | Elsevier Industry-Sponsored Symposia | N002

Mechanistic Static DDI Predictions for Supporting Drug Regulatory Submissions and Labelling

Olivier Barberan, Director of Translational Medicine Solutions, Elsevier

08:30 - 9:30 | Plenary Lecture 2 | Weston Auditorium

No way back: Moving Forward with PBPK Modeling (Why? How?)
Aleksandra Galetin, University of Manchester

09:30 - 10:00 | Refreshment Break with Posters and Exhibitors | Cricket Hall Sports Village

10:00 - 12:00 | Parallel Symposia 3 and 4

Symposium 3: Connecting AI/ML and PBPK Modeling for Lead Identification and Optimization in Early Drug Discovery | N002
Chairs: Andres Olivares-Morales, Roche and Yanran Wang, Genentech

SwiftPK: Development and Implementation of a High Throughput PBPK Framework to Inform Early Drug Discovery
Andrés Olivares-Morales, F. Hoffman La Roche, Basel, Switzerland

Implementing Machine Learning and Early PBPK Models in Early Drug Discovery
Yanran Wang, Genentech, San Francisco, California, USA

Virtual Drug Discovery and Development Combining Machine Learning and Quantitative Systems Pharmacology Approaches
Helle van den Maagdenberg, Leiden University, Leiden, the Netherlands

Symposium 4: MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury | Weston Auditorium
Chairs: Chris Goldring, University of Liverpool and Sophia Samodelov, University of Zurich

Micro RNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression. In recent years they have shown promise as circulating biomarkers of drug-induced tissue injury. This symposium will focus on current advances in understanding miRNAs as biomarkers of such drug-induced injuries, including analytical, statistical and bioinformatic approaches to their measurement and interpretation, how and whether they should be used singly or within a signature panel of markers, and particular challenges and opportunities in their application relative to more traditional protein-based biomarkers. The symposium will particularly highlight the work of the Innovative Medicines Initiative 2 academia-industry TransBioLine biomarker pipeline consortium, which aims to develop novel safety biomarkers that will reliably indicate injury to the liver, kidney, pancreas, blood vessels, and central nervous system for improved safer drug development. Our blend of Pharma and academic speakers will share recent results of the work of this consortium, ranging from the overall vision of the project, including other non-miRNA approaches, through the miRNA discovery-statistical analysis-bioinformatic pipeline, and include a well-known example of drug-induced tissue injury (liver) and an example that is less familiar (pancreas).

The Transbioline Safety Biomarker Pipeline and Focus on miRNAs
Sophia Samodelov, University of Zurich, Zurich, Switzerland

miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation
Matthias Hackl, TaMiRNA, Vienna, Austria

miRNAs as Clinical Biomarkers of Drug-induced Liver and Pancreatic Injury
Warren Glaab, Merck, West Point, Pennsylvania, USA

Statistical and Bioinformatic Strategies for Evaluating miRNAs as New Biomarkers
Anthony Evans, University of Liverpool, Liverpool, United Kingdom

12:00 - 14:00 | Exhibit Hall Hours | Cricket Hall Sports Village

12:00 - 12:30 | Pharmaron Showcase | N002

Application of Determined Apparent Permeability to Predict Disposition of Drugs

Katherine Fenner, Pharmaron

12:30 - 13:30 | Poster Presentations | Cricket Hall Sports Village

Poster Session 3: Posters P24 - P47

12:30 - 13:00: Odd-numbered posters
13:00 - 13:30: Even-numbered posters

14:00 - 15:30 | Plenary Session 3 | Weston Auditorium

Free Comms - Breaking Science

This is an open session for hot topics or informative case studies that may not fit into the themes of any other session but that are too good to miss out from. A DMDG favorite with many varied and engaging topics. It is also an opportunity for the winner of the best presentation award at the DMDG Early Careers Meeting to present their work to a wider audience.

DMPK/ADME Considerations in ADC Development
Kevin Beaumont, AstraZeneca, Cambridge, United Kingdom

Multi-modal Imaging to Accelerate Drug Discovery and Development R&D
Georges da Violante, Servier, Orleans, France

Human-relevant Methods to Assess Drug-induced Liver Injury
Chris Goldring, University of Liverpool, Liverpool United Kingdom

15:30 - 16:00 | Refreshment Break with Exhibitors | Cricket Hall Sports Village

16:00 - 17:30 | Debate | Weston Auditorium

Debate Topic: This house believes that after ADME/PK science revolutionised small molecule drug discovery in the 20th century, it has now become a disabler for productivity and candidate nomination.

The debate takes a scientific topic related to the field of DMPK with the motion phrased in a slightly provocative manner to stimulate an opinion from the audience. The session provokes great scientific exchange of ideas and opinions plus good humour both during and after the event. The debate themes are broad in nature to ensure they appeal to the diverse audience. A pre-vote is taken to establish the baseline opinion and the winners of the debate are determined by the swing in the audience vote after hearing the arguments of those speaking for and against the motion. The audience has the opportunity to ask questions after hearing from the panelists. Whilst strong opinions may be held, the DMDG debate is always conducted in a light hearted and polite manner. Questions must not be personal in nature and constructed so that speakers on both sides of the debate are able to respond. Arguments put forward by the speakers may not be their personal opinion or of the companies they represent.

Supporting Side Speakers:

Kevin Beaumont, AstraZeneca, Cambridge, United Kingdom
Jamie Henshall, UCB New Medicines, Slough, United Kingdom

Opposing Side Speakers:

Amit Kalgutkar, Pfizer, Cambridge, Massachusetts, USA
Beth Williamson, UCB New Medicines, Slough, United Kingdom